Cited by 205Epilepsy research and treatmentIon channel regulation and functionCardiac electrophysiology and arrhythmias

De novo mutations of voltage-gated sodium channel α II gene SCN2A in intractable epilepsies

Open access
Ogiwara, I., Ito, K., Sawaishi, Y., Osaka, H., Mazaki, E., Inoue, I., Montal, M., Hashikawa, T. +5 more·2009·Neurology

Abstract

BACKGROUND: Mutations of voltage-gated sodium channel alpha(II) gene, SCN2A, have been described in a wide spectrum of epilepsies. While inherited SCN2A mutations have been identified in multiple mild epilepsy cases, a de novo SCN2A-R102X mutation, which we previously reported in a patient with sporadic intractable childhood localization-related epilepsy, remains unique. To validate the involvement of de novo SCN2A mutations in the etiology of intractable epilepsies, we sought to identify additional instances. METHODS: We performed mutational analyses on SCN2A in 116 patients with severe myoclonic epilepsy in infancy, infantile spasms, and other types of intractable childhood partial and generalized epilepsies and did whole-cell patch-clamp recordings on Na(v)1.2 channels containing identified mutations. RESULTS: We discovered 2 additional de novo SCN2A mutations. One mutation, SCN2A-E1211K, was identified in a patient with sporadic infantile spasms. SCN2A-E1211K produced channels with altered electrophysiologic properties compatible with both augmented (an approximately 18-mV hyperpolarizing shift in the voltage dependence of activation) and reduced (an approximately 22-mV hyperpolarizing shift in the voltage dependence of steady-state inactivation and a slowed recovery from inactivation) channel activities. The other de novo mutation, SCN2A-I1473M, was identified in a patient with sporadic neonatal epileptic encephalopathy. SCN2A-I1473M caused an approximately 14-mV hyperpolarizing shift in the voltage dependence of activation. CONCLUSIONS: The identified de novo mutations SCN2A-E1211K, -I1473M, and -R102X indicate that SCN2A is an etiologic candidate underlying a variety of intractable childhood epilepsies. The phenotypic variations among patients might be due to the different electrophysiologic properties of mutant channels.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0b013e3181b9cebc

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Some reports describe clinical improvement with less mainstream medications, including lidocaine for infantile epileptic encephalopathy, ethosuximide for late-onset seizures, and acetazolamide for episodic ataxia, though data on generalizability are limited.

    “Some reports have described clinical improvement with less mainstream medications, including lidocaine in children with infantile epileptic encephalopathy [56,57], ethosuximide for late-onset seizures [25], and acetazolamide for episodic ataxia [28,29], though data on the generalizability of these effects are limited.”
  • The observation of seizure improvement is based only on retrospective clinical review.

    “While the observation of seizure improvement is based only on retrospective clinical review, this finding reinforces previous observations of drug response: withdrawal of phenytoin provoking status epilepticus in one case, status treated with fosphenytoin in another, 2 seizure-free on lamotrigine, and one with seizure control on lidocaine.6,12,14”
  • SCN2A is the second strongest overall association, with two truncating mutations in ASD cases and three in ID cases.

    “The second strongest overall association, with two truncating mutations in ASD cases and three such mutations in ID cases, is SCN2A, a gene previously associated with epilepsy and seizure disorders [52,53].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Sugawara T, Mazaki-Miyazaki E, Ito M, et al. Nav1.1 mu- tations cause febrile seizures associated with afebrile partial seizures. Neurology 2001;57:703-705.
  2. Dravet C, Bureau M, Oguni H, Fukuyama Y, Cokar O. Severe myoclonic epilepsy in infancy (Dravet syndrome). In: Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, eds. Epileptic Syndromes in Infancy, Childhood and Adolescence, 4th ed. Montrouge, France: John Libbey Eurotext; 2005:89 -113.

Cited by

Sorted by citations

Authors
Ogiwara, I., Ito, K., Sawaishi, Y., Osaka, H., Mazaki, E., Inoue, I., Montal, M., Hashikawa, T., Shike, T., Fujiwara, T., Inoue, Y., Kaneda, M., & Yamakawa, K.
Affiliations
Akita University (JP)
Venue
Neurology
Published
2009-09-29
Volume
73
Issue
13
Pages
1046-1053
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2061682874
Cited by
205
References
30
Citations by year
2026: 8 · 2025: 4 · 2024: 5 · 2023: 10 · 2022: 8 · 2021: 16 · 2020: 14 · 2019: 18 · 2018: 14 · 2017: 15 · 2016: 12 · 2015: 18 · 2014: 21 · 2013: 14 · 2012: 11
FWCI
5.75
Type
journal article
Language
en
Open access
Locations
  • Neurology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Ministry of Education, Culture, Sports, Science and Technology
  • Ministry of Health, Labour and Welfare
  • Fukuoka University
  • Hirosaki University
  • National Institutes of Health
  • RIKEN
  • National Institute of General Medical Sciences (GM-49711, R01GM049711)
  • RIKEN Brain Science Institute
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Epilepsy research and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Keywords
SCN2A, de novo mutations, drug-resistant epilepsy, infantile spasms, Dravet syndrome, neonatal epileptic encephalopathy, voltage dependence of activation, channel inactivation, recovery from inactivation, genotype-phenotype correlation
MeSH terms
Amino Acid Sequence, Cell Line, DNA Mutational Analysis, Epilepsies, Myoclonic, Female, Haplotypes, Humans, Infant, Newborn, Kidney, Male, Nerve Tissue Proteins, Severity of Illness Index, Spasms, Infantile, Transfection, Sodium Channels, Conserved Sequence, Protein Structure, Tertiary, Fatal Outcome, Patch-Clamp Techniques, Mutation, Missense, Young Adult, NAV1.2 Voltage-Gated Sodium Channel

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review